William Blair analyst Brandon Vazquez has reiterated their bullish stance on TCMD stock, giving a Buy rating on July 31.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brandon Vazquez has given his Buy rating due to a combination of factors including the recent positive momentum from Tactile Systems Technology’s investments, which have led to a stronger-than-expected second-quarter performance. The company exceeded sales estimates by approximately $6 million, with notable contributions from both the Lymphedema and Afflovest product lines.
Vazquez also notes that the restructuring of the salesforce and CRM integration challenges are largely resolved, indicating that the company’s strategic decisions are beginning to yield positive results. Despite conservative guidance, Vazquez sees potential for continued revenue growth and improving profitability, supported by factors such as increased sales productivity and favorable data trends. The current valuation of the company’s shares, based on future EBITDA and sales estimates, further supports the Buy recommendation.
According to TipRanks, Vazquez is an analyst with an average return of -2.9% and a 31.71% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as Neogen, PROCEPT BioRobotics, and Elanco Animal Health.
In another report released on July 31, TR | OpenAI – 4o also upgraded the stock to a Buy with a $11.00 price target.